Variants of RhD--current testing and clinical consequences.

Area of Science:

• Immunohaematology
• Blood group serology

Background:

• The Rh blood group system, specifically the D antigen (RH1), is crucial in preventing transfusion reactions and hemolytic disease.
• Numerous D variants exist, often classified as weak D or partial D, lacking clear definitions.
• DVI is a prevalent D variant linked to anti-D antibody production, necessitating specific testing.

Purpose of the Study:

• To clarify the definitions and clinical significance of Rh D variants.
• To provide evidence-based recommendations for managing patients and donors with D variants.
• To optimize blood transfusion practices and alloimmunization prevention.

Main Methods:

• Review of existing literature on Rh D variants.
• Analysis of clinical data regarding alloanti-D production associated with different D variants.
• Evaluation of current UK guidelines for D variant testing and management.

Main Results:

• The weak D/partial D dichotomy is insufficient for clinical management.
• Weak D types 1, 2, and 3 are rarely associated with alloanti-D.
• DVI is frequently implicated in anti-D production, requiring specific diagnostic reagents.

Conclusions:

• Patients with weak D types 1, 2, and 3 can be safely treated as D-positive to conserve D-negative blood supplies.
• Patients with other D variants, excluding DVI, should be managed as D-negative.
• All donors with D variant red cells, including DVI, should be classified as D-positive.